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Background-—Intracranial aneurysms (IAs), abdominal aortic aneurysms (AAAs), and thoracic aortic aneurysms (TAAs) all have a
familial predisposition. Given that aneurysm types are known to co-occur, we hypothesized that there may be shared genetic risk
factors for IAs, AAAs, and TAAs.
Methods and Results-—We performed a mega-analysis of 1000 Genomes Project-imputed genome-wide association study (GWAS)
data of 4 previously published aneurysm cohorts: 2 IA cohorts (in total 1516 cases, 4305 controls), 1 AAA cohort (818 cases, 3004
controls), and 1 TAA cohort (760 cases, 2212 controls), and observed associations of 4 known IA, AAA, and/or TAA risk loci (9p21,
18q11, 15q21, and 2q33) with consistent effect directions in all 4 cohorts. We calculated polygenic scores based on IA-, AAA-, and
TAA-associated SNPs and tested these scores for association to case-control status in the other aneurysm cohorts; this revealed
no shared polygenic effects. Similarly, linkage disequilibrium–score regression analyses did not show significant correlations
between any pair of aneurysm subtypes. Last, we evaluated the evidence for 14 previously published aneurysm risk single-
nucleotide polymorphisms through collaboration in extended aneurysm cohorts, with a total of 6548 cases and 16 843 controls
(IA) and 4391 cases and 37 904 controls (AAA), and found nominally significant associations for IA risk locus 18q11 near RBBP8 to
AAA (odds ratio [OR]=1.11; P=4.19105) and for TAA risk locus 15q21 near FBN1 to AAA (OR=1.07; P=1.19103).
Conclusions-—Although there was no evidence for polygenic overlap between IAs, AAAs, and TAAs, we found nominally significant
effects of two established risk loci for IAs and TAAs in AAAs. These two loci will require further replication. ( J Am Heart Assoc.
2016;5:e002603 doi: 10.1161/JAHA.115.002603)
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I ntracranial aneurysms (IAs), abdominal aortic aneurysms(AAAs), and thoracic aortic aneurysms (TAAs) are 3
different forms of arterial vessel wall dilatations, which can
all lead to rupture with a high case fatality rate.1–3 A
co-occurrence of AAA and TAA is known,4,5 and a weak
co-occurrence of IA and AAA has also been suggested.6,7
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Furthermore, IA, TAA, and AAA cluster within affected
families,8,9 suggesting a shared genetic background of these
3 diseases.
Genome-wide association studies (GWASs) have revealed a
handful of genetic risk factors for IA,10–12 AAA,13–16 and
TAA,17 and of these identified loci, locus 9p21 near CDKN2A,
CDKN2B, and CDKN2BAS appears to be shared by IA and
AAA.11,18 However, the heritability explained by the risk loci
identified to date is low for all 3 diseases, suggesting that
many aneurysm risk loci remain to be discovered. Among
these unknown and known risk loci, there could be shared
risk loci for multiple types of aneurysms.
In this study, we searched for shared genetic risk factors
for aneurysms. We combined individual participant GWAS
data from a Dutch and a Finnish IA cohort,12 a Dutch AAA
cohort,14 and a TAA cohort from the United States17 for a
GWAS mega-analysis across these traits. In a complementary
approach, we performed a polygenic analysis to test groups
of single-nucleotide polymorphisms (SNPs) for a joint effect
on risk across diseases. Finally, we tested the effect of bona-
fide risk SNPs from previously published IA, AAA, and TAA
GWASs on the other aneurysm types by meta-analyzing
summary statistics in the GWAS cohorts of IA, AAA, and TAA,
extended by association results of additional IA and AAA
GWAS cohorts.
Methods
Study Populations
For the GWAS mega-analysis and polygenic analysis, we used
data of subjects genotyped in previously published GWAS
cohorts of aneurysm cases and controls: 2 IA cohorts, 1 from
the Netherlands12,19,20 and 1 from Finland,11,12,21,22 1 AAA
cohort from the Netherlands14,18 and 1 TAA cohort from the
United States.17 All studies were approved by the relevant
medical ethical committees, and all participants provided
written informed consent. All study populations were previ-
ously described in detail.12,17,19,20 Below is a brief description
of each study population.
IA cases in the Dutch cohort (n=786) were admitted to the
University Medical Center Utrecht, (Utrecht, The Netherlands)
between 1997 and 2011. All cases were genotyped on
Illumina CNV370 Duo BeadChips (Illumina, San Diego, CA).
Controls (n=2089) were ascertained by the Rotterdam Study,
a population-based cohort of subjects age 45 years and older
recruited from a district in Rotterdam (The Netherlands).
These controls were genotyped on Illumina HumanHap550
BeadChips.23
The Finnish IA cohort consisted of 790 cases treated at the
Helsinki and Kuopio University hospitals and 2396 controls
that were genetically matched to cases.24 Of these, 1666
controls were extracted from the Helsinki Birth Cohort Study
(HBCS).21 Additionally, 651 controls were extracted from
anonymous donors from Kuopio University Hospital and
Helsinki and from the Health 2000 study (H2000).22 All
cases were genotyped on Illumina CNV370 Duo BeadChips,
and controls were genotyped on Illumina HumanHap550
BeadChips (HBCS) and on Illumina CNV370 Duo BeadChips
(anonymous donors and H2000).
The Dutch and the Finnish IA cohort both included cases
with ruptured and unruptured IA. Ruptured IA cases were
defined by symptoms suggestive of subarachnoid hemorrhage
(SAH) combined with subarachnoid blood on a computed
tomography (CT) scan and a proven IA at angiography
(conventional angiogram, CT- or magnetic resonance [MR]
angiogram). Unruptured IA cases were identified by CT or MR
angiography or conventional angiography in the absence of
clinical or radiological signs of SAH. Patients with fusiform IA,
possible traumatic SAH, and polycystic kidney disease were
excluded.
The AAA cohort consisted of 859 cases, predominantly
with unruptured AAA. These cases were recruited from 8
medical centers in The Netherlands, mainly when individuals
visited their vascular surgeon in the outpatient clinic or, in
some cases, during hospital admission for elective or
emergency AAA surgery. An AAA was defined as an infrarenal
aorta diameter of ≥30 mm. Mean AAA diameter was
58.4 mm. Of these patients, 530 had undergone surgery,
including 43 with rupture. Genotyping was performed on
Illumina HumanHap610 chips.14 As controls, we included
3110 Dutch subjects who were recruited as part of the
Nijmegen Biomedical Study (n=1832) and the Nijmegen
Bladder Cancer Study (n=1278).19,20 These controls were
genotyped on Illumina CNV370 Duo BeadChips.
The TAA cohort consisted of 765 cases with either an
ascending TAA without dissection (n=401) or with a type A
and/or type B aortic dissection (n=364). All cases were more
than 30 years old, did not have a first-degree relative with
TAA or dissection, and had no evidence of a syndromic form
of TAA or dissection. Samples were genotyped with Illumina
CNV370-Quad BeadChips. Controls (n=2229) were included
from the Wellcome Trust Case-Control Consortium (WTCCC)
1958 Birth Cohort (n=1355), and from the US National
Institute of Neurological Disorders and Stroke (NINDS)
Repository’s Neurologically Normal Control Collection
(n=874).
Quality Control
We performed quality control (QC) in each of the 4 cohorts
separately, using PLINK software (version 1.07).25 After
removal of SNPs with A/T or C/G alleles and SNPs that
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were not called in any individual, we performed sample QC
and SNP QC.
Sample QC was performed after merging cases and controls,
using a subset of common, high-quality SNPs (as defined by
SNPs without deviation from Hardy-Weinberg equilibrium [HWE;
P>0.001], with high minor allele frequency [MAF; >20%], and
with low rate of missing genotypes [<1%]). Linkage disequilib-
rium (LD) pruning (r2>0.5) was performed. Subjects were
removed based on the following 3 criteria: missing genotypes
(subjects with a call rate below 95% were removed); heterozy-
gosity (subjects were excluded if the inbreeding coefficient
deviated more than 3 SDs from the mean); and cryptic
relatedness (by calculating identity-by-descent [IBD] for each
pair of individuals). In each pair with an IBD proportion of >20%,
a subject was excluded, if it exhibited distant relatedness with
more than 1 individual. For case-control pairs, we removed the
control subject. In the case-case or control-control pairs, the
subject with the lowest call rate was excluded.
Using these common, high-quality SNPs, we performed
principal components (PCs) analysis using EIGENSTRAT on
the remaining study subjects and HapMap-CEU subjects. We
excluded SNPs from 3 regions with known long-distance LD:
the major histocompatibility region (chr6: 25.8–36 Mbp); the
chromosome 8 inversion (chr8: 6–16 Mbp); and a chromo-
some 17 region (chr17: 40–45 Mbp). We created PC plots
with the first 4 PCs, using R software (version 2.11; R
Foundation for Statistical Computing, Vienna, Austria).26
Based on visual inspection of these plots, we excluded
subjects that appeared to be outliers with respect to the
CEU (Utah residents with ancestry from northern and
western Europe) or the study population. After outlier
removal, we recomputed PCs for them to be included as
covariates in the logistic regression models. PC plots after
outlier removal are shown in Figure 1.
After sample QC, we excluded SNPs with more than 2%
missing genotypes, MAF <1%, missing genotype rate higher
A B
C D
Figure 1. Principal component analysis (PCA) plots of IA, AAA, and TAA GWAS cohorts. (A) Dutch IA GWAS cohort; (B) Finnish IA GWAS cohort;
(C) AAA GWAS cohort; (D) TAA GWAS cohort. These figures show PCA2 values plotted against PCA1 values for each individual in the 4 GWAS
cohorts (Dutch IA and Finnish IA, AAA, and TAA) of the aneurysm mega-analysis, after removal of outliers from quality control. AAA indicates
abdominal aortic aneurysm; GWAS, genome-wide association study; IA, intracranial aneurysm; TAA, thoracic aortic aneurysm.
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than MAF, and HWE deviation (P<0.001). Because cases and
controls had been genotyped separately, we performed these
QC steps in each study cohort separately and again after
merging cases and controls. We also removed SNPs with a
differential degree of missing genotypes between cases and
controls (P<19105; chi-squared test).
Imputation
For each case-control data set, we performed genotype
imputation using the prephasing/imputation step-wise
approach implemented in IMPUTE2 and SHAPEIT (chunk size
of 3 Mb and default parameters).27,28 The imputation refer-
ence set consisted of 2184 phased haplotypes from the full
1000 Genomes Project data set (February 2012; 40 318 253
variants). All genomic locations are given in NCBI Build
37/UCSC hg19 coordinates. After imputation, SNPs with an
imputation accuracy score <0.6 or MAF <0.5% were
excluded.
GWAS Mega-Analysis Across IA, AAA, and TAA
We performed a mega-analysis on all 4 GWAS cohorts.
Association testing was carried out in PLINK25 using
imputed SNP dosages. We included as covariates the first
4 PCs and an indicator variable to adjust for each case-
control data set. SNPs with P<59108 were considered as
genome-wide significant. We also performed a GWAS on
each cohort separately and a combined analysis of only the
Dutch and Finnish IA cohort, which was needed for the
polygenic analysis as described below. We calculated
genomic inflation factors (kGC) for each GWAS and the
mega-analysis, defined as the ratio of the median of
the empirically observed distribution of the test statistic to
the expected median.29
We calculated the statistical power for detecting a
significant association (P<59108) in the mega-analysis
using the genetic power calculator.30 In case of a risk
allele frequency of 10%, the resulting power is 0.03% at a
relative risk of 1.1 per allele, and 68.7% at a relative risk
of 1.3 per allele, assuming additive effects. In case of a
higher risk allele frequency of 20%, the power is 0.3% at a
relative risk of 1.1 and 98.9% at a relative risk of 1.3 per
allele.
Polygenic Analysis
We performed polygenic analysis as previously described.31
We used the IA cohorts (Dutch and Finnish cohorts combined)
as a discovery sample and the AAA and TAA cohorts as 2
separate target samples, and vice versa, in all possible
combinations (6 in total).
We pruned the SNPs genotyped or imputed in the
discovery sample, using an LD threshold of r2>0.1. For each
genomic region, we chose SNPs with the lowest P values in
the GWAS of the discovery sample, in order to retain a set of
independent, maximally associated SNPs. Next, we created
sets of SNPs with disease association in the discovery sample
at 12 different significance thresholds, increasing from
P<59108 to P<0.5. For each SNP set, we calculated a
polygenic risk score in each individual of target sample as
follows:
Genetic score ¼ b1x1 þ b2x2 þ    þ bnxn;
where xi is the estimated allele dosage (between 0 and 2) in a
given individual, and bi is the effect size from the GWAS in the
discovery sample for the ith SNP. We tested the association
between these polygenic risk scores and case-control status
in the target sample using logistic regression, adjusting for
the first 4 PCs in the target sample. For analyses involving the
combined IA cohort as target sample, we also adjusted for
population (Finnish or Dutch). For analyses involving the IA
and AAA cohorts as target and discovery sample, we also
adjusted for the genotype of the known shared IA/AAA risk
SNPs on locus 9p21.11,18
Table 1. Overview of Study Populations Used for the Specific
Lookup of Known IA, AAA, and TAA Risk SNPs
Cohort Cases (n) Controls (n)
IA
Netherlands 717 1987
Finland 799 2317
Japan 1 288 194
Japan 2 1383 5484
USA+ 2617 2548
@neurIST 717 3296
Total 6548 16 843
AAA
Netherlands 812 2998
Iceland 430 27 712
USA 724 1604
Aneurysm Consortium 1846 5605
New Zealand 1 608 612
New Zealand 2 400 384
Total 4391 37 904
TAA
USA 760 2212
AAA indicates abdominal aortic aneurysm; IA, intracranial aneurysm; SNPs, single-
nucleotide polymorphisms; TAA, thoracic aortic aneurysm.
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LD Score Regression: Heritability Estimation and
Genetic Correlation Analyses
We used LD score regression (LDSC) for heritability estima-
tion and genetic correlation analysis.32 These analyses were
applied to the same 4 GWAS datasets as used in the GWAS
mega-analysis and polygenic analysis described above (Dutch
IA and Finnish IA, AAA, and TAA), but for this analysis we
only included genotyped SNPs (after QC), and not imputed
SNPs.
GWAS cohorts
Genotyping
2. Polygenic analysis
Logistic regression for each combination:
Disease status (IA / AAA / TAA vs control) <-> polygenic score + PCs + sex
Illumina CNV370
Duo /
HumanHap550
BeadChip
Illumina CNV370
Duo /
HumanHap550
BeadChip
Illumina
HumanHap610 /
CNV370 Duo
BeadChip
Illumina CNV370-
Quad BeadChip
Sample QC, SNP QC and imputation per GWAS cohort
1. GWAS mega-analysis
3094 cases, 9507 controls
Logistic regression:
Disease status (aneurysm vs control) <-> SNP dosage + PCs + GWAS cohort indicator variable
IA (Netherlands)
786 cases
2089 controls
IA (Finland)
790 cases
2396 controls
AAA
859 cases
3110 controls
TAA
765 cases
2229 controls
IA (Netherlands + Finland) AAA TAA
3. Specific look-up of known aneurysm risk SNPs in IA, AAA and TAA
Extraction of 14 aneurysm risk SNPs from GWAS results
(for IA and AAA: inverse-variance fixed-effects meta-analysis)
6 IA GWAS cohorts
6548 cases, 16843 controls
6 AAA GWAS cohorts
4391 cases, 37904 controls
1 TAA GWAS cohort
760 cases, 2212 controls
Figure 2. Work-flow figure. This figure gives an overview of the study methods. AAA indicates abdominal
aortic aneurysm; CNV, copy number variation; GWAS, genome-wide association study; IA, intracranial
aneurysm; PCs, principal components; QC, quality control; SNP, single-nucleotide polymorphism; TAA,
thoracic aortic aneurysm.
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LDSC is a new approach that implements LD-score
weighted linear regression methods to estimate the variance
(and covariance) explained by all SNPs on the whole genome
for a complex trait. This method can distinguish true
polygenicity from confounding effects attributed to population
structure and cryptic relatedness. Under a polygenic model,
the more-genetic variants an index variant tags, the more the
probability that the index variant will be significant.32 Under
this reasoning, the expected v2 statistic of variant j can be
constructed as follows:
E½v2j‘j ¼ Nh2‘j=Mþ Naþ 1;
where N is the sample size; M is the number of SNPs, so that
h2/M is the average heritability per SNP; a measures the
contribution of confounding biases, like cryptic relatedness
and population stratification; and ‘j ¼
P
k r
2
jk is the sum of
the r2 values to all variants that a variant j tags, which is
called the LD score of variant j. The LD score can be
calculated using reference panel containing whole genome
information of the population. For the analysis of the
European population, we used the LD estimates that are
from the European-ancestry samples in the 1000 Genomes
Project.33 Details were elaborated from the LDSC’s GitHub
repository.32
In addition to estimating heritability using LDSC, we also
used LDSC to estimate genetic correlation (q) between each
pair of 3 diseases (AAA, IA, and TAA).34 We investigated the
Dutch and Finnish IA cohort separately in this analysis, and
also tested the correlation between these two IA data sets, to
evaluate the genetic correlation within 1 disease.
Effects of Previously Established Risk SNPs
We investigated the effect of established IA,10–12 AAA,13–16
and TAA17 risk SNPs from previous GWASs in each of the
other aneurysm types. We looked up the effect sizes and
significance of these SNPs in separate case-control data sets
for IA, AAA and TAA beyond the individual-participant data
sets already described above. We did not have access to all
genotype data of these data sets, but we obtained association
results for these candidate SNPs only. For IA, we used GWAS
results of 2 Japanese cohorts,11 a combined cohort of several
previously IA studies that recruited subjects from mainly
North America, but also Poland and Australia (further referred
to as “USA+”),35 and the @neurIST study.11 For AAA, we used
GWAS results of a cohort from Iceland, the United Kingdom,
the United States, and 2 cohorts from New Zealand.15,16,36,37
For TAA, no additional GWAS cohorts are currently available,
to our knowledge. The sample sizes and other details per
cohort are listed in Table 1. In total, the target samples
available for this lookup analysis contained 6548 cases and
16 843 controls for IA, 4391 cases and 37 904 controls for
AAA, and 760 cases and 2212 controls for TAA.
We combined the GWAS results for the selected SNPs in the
extended IA and AAA cohorts using an inverse-variance fixed-
effects meta-analysis. For each SNP, we first calculated z
scores from the provided P values of each GWAS, and summed
the z scores across all studies using the effective sample size of
each study as weights.38 The resulting z scores were converted
into chi-square values and 2-sided P values. We applied
Bonferroni correction for performing 28 association tests (14
selected SNPs tested in 2 aneurysm types) and considered
associations with P<1.89103 (0.05/28) as significant.
Figure 2 gives an overview of the methods described above.
Results
Study Populations
Table 2 shows the numbers of cases, controls, and SNPs of all
4 cohorts after QC and imputation. Quantile-quantile (QQ)
plots for each GWAS per cohort are shown in Figure 3.
Table 2. Baseline Characteristics After Quality Control and Imputation of the Study Populations Used for the Mega-Analysis and
Polygenic Analysis of IA, AAA, and TAA GWAS Data
Characteristics
Study Cohort
IA (Netherlands) IA (Finland) AAA TAA
Cases, n 717 799 818 760
Women, % 64.3 57.8 10.5 34.3
Controls, n 1988 2317 3004 2212
Women, % 56.2 57.2 37.7 53.0
SNPs, n 10 683 725 10 524 028 10 684 772 10 750 239
Genomic inflation factor 1.10 1.06 1.04 1.05
AAA indicates abdominal aortic aneurysm; GWAS, genome-wide association study; IA, intracranial aneurysm; SNP, single-nucleotide polymorphism; TAA, thoracic aortic aneurysm.
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Figure 3. Quantile-quantile (QQ) plots of IA, AAA, and TAA GWAS and the aneurysm mega-analysis. A, Dutch IA
GWAS; (B) Finnish IA GWAS; (C) AAA GWAS; (D) TAA GWAS; (E) aneurysm mega-analysis. These QQ plots show the
observed distribution of P values (black dots) plotted against the expected distribution of P values (blue line) on a
negative log10 scale, for each of the 4 GWAS (Dutch IA and Finnish IA, AAA, and TAA) and for all cohorts combined in
the aneurysm mega-analysis. Genomic inflation factors (kGC) per study, defined as the ratio of the median of the
empirically observed distribution of the test statistic to the expected median, are also shown. AAA indicates abdominal
aortic aneurysm; GWAS, genome-wide association study; IA, intracranial aneurysm; TAA, thoracic aortic aneurysm.
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GWAS Mega-Analysis Across IA, AAA, and TAA
In total, 3094 cases, 9507 controls, and 9 245 988 SNPs
were available for the mega-analysis across all 4 aneurysm
cohorts (kGC=1.06). The results of this mega-analysis are
shown in a Manhattan plot (Figure 4). We found 4 genome-
wide significant loci, though all these loci were previously
described as risk loci for IA, AAA, and/or TAA. The direction of
effect for these loci was consistent across all four aneurysm
cohorts (see forest plots in Figure 5). First, SNPs at the
known IA and AAA risk locus 9p21 near CDKN2A, CDKN2B,
and CDKN2BAS were associated.11,18 The strongest associ-
ation at this locus was found for rs7866503, with
P=2.191013. The second association was found for SNPs
at the known IA risk locus 18q11 near RBBP8,11 with the
strongest association for rs8087799 (P=1.69109). The third
association was found for SNPs at the known TAA risk locus
15q21 near FBN1,17 with the strongest association for
rs595222 (P=1.09108). The fourth association was found
for rs919433 (P=4.69108), which is located at 2q33 near
ANKRD44. The same SNP was previously found to be
associated with IA in a Finnish and Dutch population.24 This
SNP is also in strong LD (r2=0.7) with a nearby SNP
(rs700651), which was previously found to be associated
with IA in a Dutch, Finnish, and Japanese population,12 but did
not reach genome-wide significance after adding other
populations of IA patients.11
Polygenic Analysis
Next, we investigated whether groups of SNPs associated
with 1 type of aneurysm (eg, IA) were also associated with
the other types (eg, AAA or TAA). The results of these
polygenic analyses with the IA, AAA, and TAA GWAS cohorts
are shown in Tables 3 through 8 and in Figure 6. No SNP
sets with a significant joint effect on another aneurysm type
were observed, except for a small group of 7 SNPs
associated with IA with P<106. This SNP set was associated
with AAA with P=59103 (Table 7). When taking a closer
look at this SNP set, it appears that the polygenic associ-
ation is driven by 2 SNPs (rs36071109 at 2q33;
PAAA=2.3910
3; and rs4330012 at 18q11; P (cursive)AAA=
1.39102), both in very strong LD to genome-wide signif-
icant SNPs in our mega-analysis described above. (The
pleiotropic 9p21 locus shared by IA and AAA had already
been adjusted for.)
Figure 4. Manhattan plot of the aneurysm GWAS mega-analysis. This Manhattan plot shows the P values
of all SNPs with an association with P<104 to disease (IA, AAA, or TAA). P values on the y-axis are
presented on an inverse log scale. The x-axis represents the genomic position of each SNP. The red
horizontal line represents P=59108, the cut-off value for genome-wide association. Index SNPs with
P<19106 are depicted as diamonds, whereas SNPs in the same LD block as these SNPs are depicted as
yellow and red dots. AAA indicates abdominal aortic aneurysm; GWAS, genome-wide association study; IA,
intracranial aneurysm; LD, linkage disequilibrium; SNP, single-nucleotide polymorphism; TAA, thoracic aortic
aneurysm.
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Figure 5. Forest plots of significant SNPs from the aneurysm mega-analysis. A, rs7866503 (risk
allele T) at locus 9p21; (B) rs8087799 (risk allele A) at locus 18q11; (C) rs595244 (risk allele T) at locus
15q21; (D) rs919433 (risk allele A) at locus 2q33. These figures show forest plots for each of the 4
genome-wide significant SNPs from the mega-analysis of IA, AAA, and TAA GWAS cohorts. AAA
indicates abdominal aortic aneurysm; f_ca(n), risk allele frequency in cases (number of cases); f_co(n),
risk allele frequency in controls (number of controls); het_P, P value for heterogeneity; IA, intracranial
aneurysm; info, imputation accuracy score; ln(OR), natural log of odds ratio; OR, odds ratio; P_value, P
value for association of risk allele in aneurysm cohort; SNP, single-nucleotide polymorphism; STDerr,
standard error; TAA, thoracic aortic aneurysm.
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LD Score Regression: Heritability Estimation and
Genetic Correlation Analyses
We attempted to analyze heritability of the 3 aneurysm
subtypes using LDSC. The estimated heritability was 0.15
for AAA, 0.31 for the Finnish IA cohort, 0.34 for the Dutch
IA cohort, and 0.40 for TAA (Table 9). These estimates are
smaller than the twin-based estimates as reported in the
literature (0.41 for IA,39 0.70 for AAA,16 and unknown for
TAA), but the SEs are large, so the differences are not
statistically significant. Note that methods estimating
heritability using SNP data can often underestimate the
heritability if the SNP set does not tag all underlying causal
variants.
We then performed genetic correlation analyses
(Table 10). We found that all pairs did not show statistically
significant genetic correlations (P>0.05). The direction of
correlation was either close to zero or positive, but the SE
values were large. As expected, we observed the largest
genetic correlation between the 2 cohorts of the same IA
disease (q=1.59). However, this correlation was also not
significant (P=0.09; SE=0.93).
Effects of Previously Established Risk SNPs
Table 11 shows the results of the lookup of previously
published aneurysm risk SNPs in IA, AAA, and TAA GWAS
results. Besides the 2 IA and AAA risk SNPs at 9p21,
which are associated with IA and AAA but not TAA, we
observed 2 SNPs with significant associations to another
aneurysm type after multiple testing correction. First, the
IA risk SNP rs11661542 at 18q11 near RBBP8 was
associated with AAA (odds ratio [OR]=1.11; P=4.19105).
Second, the TAA risk SNP rs2118181 at 15q21 near FBN1
Table 3. Polygenic Analysis: AAA-Associated SNPs Tested for
Association With TAA Case-Control Status
Threshold (P)* SNPs (n)† P Value‡ Direction of Effect
59108 0 NA NA
19107 1 0.269 +
19106 4 0.262 +
19105 21 0.481 +
19104 181 0.979 +
19103 1417 0.815 +
0.01 10 075 0.294 +
0.05 38 528 0.549 +
0.1 67 187 0.614 
0.2 113 644 0.823 
0.3 151 807 0.773 
0.4 183 891 0.765 
0.5 211 723 0.611 
104 to 103 1236 0.787 +
103 to 0.01 8658 0.273 +
0.01 to 0.05 28 453 0.972 
0.05 to 0.1 28 659 0.964 
0.1 to 0.2 46 457 0.115 
0.2 to 0.3 38 163 0.745 
0.3 to 0.4 32 084 0.904 
0.4 to 0.5 27 832 0.0915 
AAA indicates abdominal aortic aneurysm; IA, intracranial aneurysm; NA, not applicable;
SNPs, single-nucleotide polymorphisms; TAA, thoracic aortic aneurysm.
*P value threshold for inclusion of IA-, AAA-, or TAA-associated SNPs in each polygenic
model.
†
Number of SNPs included in each polygenic model.
‡
P value for association of the polygenic model with IA, AAA or TAA case-control status.
Table 4. Polygenic Analysis: TAA-Associated SNPs Tested for
Association With AAA Case-Control Status
Threshold (P)* SNPs (n)† P Value‡ Direction of Effect
59108 1 0.581 +
19107 1 0.581 +
19106 1 0.581 +
19105 25 0.853 +
19104 148 0.971 
19103 1350 0.292 +
0.01 10 021 0.579 +
0.05 39 120 0.902 
0.1 67 736 0.944 
0.2 114 125 0.815 
0.3 151 712 0.956 
0.4 183 843 0.958 
0.5 211 170 0.965 
104 to 103 1202 0.252 +
103 to 0.01 8671 0.877 
0.01 to 0.05 29 099 0.801 
0.05 to 0.1 28 616 0.953 
0.1 to 0.2 46 389 0.643 +
0.2 to 0.3 37 587 0.255 
0.3 to 0.4 32 131 0.997 
0.4 to 0.5 27 327 0.422 +
AAA indicates abdominal aortic aneurysm; IA, intracranial aneurysm; SNPs,
single-nucleotide polymorphisms; TAA, thoracic aortic aneurysm.
*P value threshold for inclusion of IA-, AAA-, or TAA-associated SNPs in each polygenic
model.
†
Number of SNPs included in each polygenic model.
‡
P value for association of the polygenic model with IA, AAA or TAA case-control status.
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was associated with AAA (OR=1.07; P=1.19103). The
other TAA risk SNP rs10519177, which lies at the same
locus but is independent from rs2118181, showed a
suggestive, but not statistically significant, association to
AAA (OR=1.01; P=0.016). For both significant associa-
tions, the direction of effect was concordant in all but 1 of
the 6 AAA cohorts in the analysis, with no significant
heterogeneity in the meta-analysis of the 6 cohorts
(PCochran’s Q=0.11 for rs11661542 at 18q11 and 0.45 for
rs2118181 at 15q21).
Discussion
In this study, we have applied multiple analytic approaches
to detect a possible genetic overlap between IA, TAA, and
AAA. By performing a GWAS mega-analysis and polygenic
analysis, we considered both sharing of significant risk loci
with individually large effects on disease risk, as well as a
cumulative effect of many loci with individually weak
effects. Although we did not find novel shared aneurysm
risk loci that were previously not described as risk loci for
IA, AAA, and/or TAA, we did find some evidence for a
shared genetic background of IA, AAA, and TAA. In the
GWAS mega-analysis across IA, AAA, and TAA, we detected
genome-wide significant associations for SNPs at 4 loci:
9p21, 18q11, 15q21, and 2q33. These were all previously
described to be associated with IA, AAA, or TAA, but in this
study, they showed globally consistent effects across all 3
aneurysm types. Polygenic analysis did not reveal any
groups of weakly IA-, AAA-, or TAA-associated loci with a
joint effect on other aneurysm types. Similarly, LD-score
regression analyses did not show significant correlations
between any pair of aneurysm subtypes. The correlation
between 2 cohorts of the same subtype (IA) was relatively
Table 5. Polygenic Analysis: IA-Associated SNPs Tested for
Association With TAA Case-Control Status
Threshold (P)* SNPs (n)† P Value‡ Direction of Effect
59108 2 0.464 +
19107 3 0.459 +
19106 7 0.964 +
19105 36 0.361 
19104 263 0.24 
19103 1738 0.32 
0.01 11 365 0.681 +
0.05 40 885 0.088 +
0.1 69 990 0.608 +
0.2 116 737 0.931 
0.3 154 387 0.612 
0.4 184 519 0.633 
0.5 209 893 0.625 
104 to 103 1475 0.572 
103 to 0.01 9627 0.318 +
0.01 to 0.05 29 520 0.04 +
0.05 to 0.1 29 105 0.0699 
0.1 to 0.2 46 747 0.193 
0.2 to 0.3 37 650 0.105 
0.3 to 0.4 30 132 0.951 
0.4 to 0.5 25 374 0.864 
AAA indicates abdominal aortic aneurysm; IA, intracranial aneurysm; SNPs, single-
nucleotide polymorphisms; TAA, thoracic aortic aneurysm.
*P value threshold for inclusion of IA-, AAA-, or TAA-associated SNPs in each polygenic
model.
†
Number of SNPs included in each polygenic model.
‡
P value for association of the polygenic model with IA, AAA or TAA case-control status.
Table 6. Polygenic Analysis: TAA-Associated SNPs Tested for
Association With IA Case-Control Status
Threshold (P)* SNPs (n)† P Value‡ Direction of Effect
59108 1 0.245 +
19107 1 0.245 +
19106 1 0.245 +
19105 25 0.0957 
19104 148 0.658 
19103 1347 0.741 
0.01 10 030 0.547 +
0.05 39 150 0.72 +
0.1 67 783 0.693 +
0.2 114 079 0.554 +
0.3 151 575 0.538 +
0.4 183 611 0.651 +
0.5 210 876 0.675 +
104 to 103 1199 0.588 
103 to 0.01 8683 0.592 +
0.01 to 0.05 29 120 0.965 +
0.05 to 0.1 28 633 0.813 +
0.1 to 0.2 46 296 0.487 +
0.2 to 0.3 37 496 0.761 +
0.3 to 0.4 32 036 0.409 +
0.4 to 0.5 27 265 0.84 +
AAA indicates abdominal aortic aneurysm; IA, intracranial aneurysm; SNPs, single-
nucleotide polymorphisms; TAA, thoracic aortic aneurysm.
*P value threshold for inclusion of IA-, AAA-, or TAA-associated SNPs in each polygenic
model.
†
Number of SNPs included in each polygenic model.
‡
P value for association of the polygenic model with IA, AAA or TAA case-control status.
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high, but also not significant. The absence of novel shared
loci, a polygenic association or a genetic correlation can be
attributed to the modest sample size and power, certainly
in comparison to community-wide efforts for coronary
artery disease.40 It may therefore be premature to claim
that there are genuinely no novel shared loci or shared
polygenic effects for IA, AAA, and TAA.
After testing the association of bona-fide aneurysm risk
loci in other aneurysm types in much larger aneurysm GWAS
cohorts (consisting of the mega-analysis data plus additional
IA and AAA GWAS cohorts), we found nominally significant
associations of the IA risk locus 18q11 and the TAA risk locus
15q21 to AAA, both of which were previously unknown to be
associated with AAA. The 15q21 locus has reported biological
functions that could plausibly be related to aneurysm
development, because it encompasses the FBN1 gene, which
encodes fibrillin-1, an extracellular matrix protein in the
elastic fibers of the aortic wall. Mutations in FBN1 cause
Marfan syndrome, which is often associated with (mainly
thoracic) aortic aneurysms.17
There are extensive differences in pathophysiology and
epidemiological risk factors between the 3 diseases. IAs are
mostly saccular-shaped dilatations, whereas AAAs and TAAs
are more often fusiform; the vessel wall structure differs
between the locations where IA, AAA, and TAA occur; and
atherosclerosis has a clear role in AAA, in contrast to IA
and TAA.41–44 However, there have been previous reports of
a co-occurrence of AAA and TAA4,5 and, to a lesser extent,
of IA and aortic aneurysms.6,7 Also, IA mainly co-occurs
with AAA and TAA within families,8,9 so genetic sharing
between IA, AAA, and TAA could theoretically be present in
the familial form, but not in sporadic cases (which were
primarily studied here). For example, mutations in TGFBR1
and TGFBR2 were found in families in which all 3 aneurysm
Table 7. Polygenic Analysis: IA-Associated SNPs (From
Dutch and Finnish IA Cohorts Combined) Tested for
Association With AAA Case-Control Status
Threshold (P)* SNPs (n)† P Value‡ Direction of Effect
59108 2 0.531 +
19107 3 0.016 +
19106 7 5.079103 +
19105 36 1.369102 +
19104 256 0.694 +
19103 1725 0.365 
0.01 11 355 0.986 +
0.05 40 855 0.505 +
0.1 69 919 0.329 
0.2 116 610 0.298 
0.3 154 280 0.349 
0.4 184 378 0.326 
0.5 209 684 0.251 
104 to 103 1469 0.401 
103 to 0.01 9630 0.673 +
0.01 to 0.05 29 500 0.343 
0.05 to 0.1 29 064 0.291 
0.1 to 0.2 46 691 0.503 
0.2 to 0.3 37 670 0.929 +
0.3 to 0.4 30 098 0.568 
0.4 to 0.5 25 306 0.085 
AAA indicates abdominal aortic aneurysm; IA, intracranial aneurysm; SNPs, single-
nucleotide polymorphisms; TAA, thoracic aortic aneurysm.
*P value threshold for inclusion of IA-, AAA-, or TAA-associated SNPs in each polygenic
model.
†
Number of SNPs included in each polygenic model.
‡
P value for association of the polygenic model with IA, AAA, or TAA case-control status.
Table 8. Polygenic Analysis: AAA-Associated SNPs Tested for
Association With IA Case-Control Status
Threshold (P)* SNPs (n)† P Value‡ Direction of Effect
59108 0 NA NA
19107 1 0.789 
19106 4 0.589 +
19105 21 0.481 +
19104 181 0.826 +
19103 1420 0.914 
0.01 10 094 0.362 +
0.05 38 571 0.72 +
0.1 67 304 0.596 +
0.2 113 818 0.827 +
0.3 152 058 0.874 +
0.4 184 216 0.700 +
0.5 212 087 0.585 +
104 to 103 1239 0.834 
103 to 0.01 8674 0.318 +
0.01 to 0.05 28 477 0.239 +
0.05 to 0.1 28 733 0.592 +
0.1 to 0.2 46 514 0.549 +
0.2 to 0.3 38 240 0.153 +
0.3 to 0.4 32 158 0.163 +
0.4 to 0.5 27 871 0.162 +
AAA indicates abdominal aortic aneurysm; IA, intracranial aneurysm; NA, not applicable;
SNPs, single nucleotide polymorphisms; TAA, thoracic aortic aneurysm.
*P value threshold for inclusion of IA-, AAA-, or TAA-associated SNPs in each polygenic
model.
†
Number of SNPs included in each polygenic model.
‡
P value for association of the polygenic model with IA, AAA, or TAA case-control status.
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Figure 6. Polygenic analysis results. (A) AAA-associated SNPs tested for association with TAA case-control status; (B) TAA-associated SNPs
tested for association with AAA case-control status; (C) IA-associated SNPs tested for association with TAA case-control status; (D) TAA-
associated SNPs tested for association with IA case-control status; (E) IA-associated SNPs tested for association with AAA case-control status;
(F) AAA-associated SNPs tested for association with IA case-control status. We created polygenic scores based on IA-, AAA-, and TAA-associated
SNPs at different P value thresholds and tested these scores for association to case-control status in GWAS cohorts of IA, AAA, and TAA in each
possible combination between these phenotypes. The figures show the resulting P values of the association tests (left y-axis) for each polygenic
model (x-axis), with the corresponding number of SNPs in each model (right y-axis). AAA indicates abdominal aortic aneurysm; GWAS, genome-
wide association study; IA, intracranial aneurysm; SNP, single-nucleotide polymorphism; TAA, thoracic aortic aneurysm.
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types occur.8 Furthermore, a genetic linkage study in 26
families with both IA and AAA or TAA found linkage peaks at
locus 6p23 and 11q24.45 Independent linkage studies on IA,
AAA, and TAA also found linkage peaks at 11q24.46 We did
not find associations of these loci in our study, which can
be explained by our focus on the sporadic aneurysm cases,
in contrast to the familial cases in the linkage studies.
In conclusion, our study results do not reveal new risk loci
shared between IA, AAA, and TAA, but the effects of
established IA, AAA, and TAA risk loci in other aneurysm
types do suggest a shared genetic background. Future studies
with larger sample sizes should increase the statistical power
to detect common genetic variants with a smaller effect on
disease risk, and to draw definitive conclusions on genetic
correlation between aneurysm subtypes.
Appendix
Aneurysm Consortium
Matthew J. Bown, Seamus C. Harrison, Athanasios Saratzis,
Ana Verissimo, Benjamin J. Wright, Suzannah Bumpstead,
Annette F. Baas, Solveig Gretarsdottir, Stephen A. Badger,
Anne H. Child, Rachel E. Clough, Gillian Cockerill, Hany Hafez,
D. Julian A. Scott, Simon Futers, Soroush Sohrabi, Alberto
Smith, Matthew M. Thompson, Frank M. van Bockxmeer,
Stefan E. Matthiasson, Gudmar Thorleifsson, Unnur
Thorsteinsdottir, Jan D. Blankensteijn, Joep A. W. Teijink,
Cisca Wijmenga, Jacqueline de Graaf, Lambertus A. Kiemeney,
Jutta Palmen, Andrew J. Smith, Jes S. Lindholt, Declan T.
Bradley, Matthew Waltham, Sarah Edkins, Rhian Gwilliam,
Sarah E. Hunt, Simon Potter, Jonathan Golledge, Per Eriksson,
Paul E. Norman, Janet T. Powell, Kari Stefansson, John R.
Thompson, Steve E. Humphries, Robert D. Sayers, Panos
Deloukas, and Nilesh J. Samani.
Vascular Research Consortium of New Zealand
Gregory T. Jones, L. Victoria Phillip, Andre M. van Rij,
Geraldine B. Hill, Michael J. A. Williams, Ian A. Thomson, Jo
Krysa, Gerard T. Wilkins, Tony R. Merriman, Thodor M.
Vasudevan, David R. Lewis, Ross D. Blair, and Andrew A. Hill.
Acknowledgments
We thank the staff and participants of the ARIC study for their
important contributions. We also thank the NINDS and WTCCC for
giving us the use of their control data, used for the TAA GWAS. We
are also grateful to the staff from the Rotterdam Study and the
participating general practitioners and pharmacists. We also thank
Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera, and
Marjolein Peters, MSc, and Carolina Medina-Gomez, MSc, for their
help in creating the GWAS database of the Rotterdam Study.
The following clinical centers and collaborators contributed to the
sample and data collection of the @neurIST project (in order of
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rs1166154211 RBBP8 18 C 4.19105 1.11 +++++ 0.11 0.08 1.11 NA NA
SNP—AAA Gene Chr RA
IA TAA
P Value OR Dir* PCochran’s Q P Value OR Dir* PCochran’s Q
rs1075727818 CDKN2BAS 9 G 5.991017 1.30 +++. . . 0.81 0.42 1.05 NA NA
rs146653513 LRP1 12 C 0.95 1.00 +++ 0.66 0.07 1.12 NA NA
rs702548614 DAB2IP 9 A 0.25 1.03 ++++ 0.36 0.70 0.97 NA NA
rs59983916 SORT1 1 G 0.41 0.97 +. . . 0.76 0.42 0.94 NA NA
rs651172015 LDLR 19 G 0.15 1.07 ++.. 0.09 0.05 1.21 NA NA
SNP—TAA Gene Chr RA
IA AAA
P Value OR Dir* PCochran’s Q P Value OR Dir* PCochran’s Q
rs1051917717‡ FBN1 15 G 0.99 1.00 ++++ 0.25 0.016 1.01 ++++ 0.32
rs211818117‡ FBN1 15 G 0.20 0.96 +++ 0.08 1.19103 1.07 +++++ 0.45
Lookup results in different cohorts were combined per subtype, using an inverse-variance fixed-effects meta-analysis. AAA indicates abdominal aortic aneurysm; Chr, chromosome; Dir,
direction of effect; IA, intracranial aneurysm; OR, odds ratio; PCochran’s Q, P value from Cochran’s Q test; RA, risk allele; SNP, single nucleotide polymorphism; TAA, thoracic aortic aneurysm.
*Direction of effect per cohort. For AAA, directions correspond to the cohorts “Iceland,” “Netherlands,” “USA,” “Aneurysm Consortium,” “New Zealand 1,” and “New Zealand 2,”
respectively. For IA, directions correspond to the cohorts “Netherlands,” “Finland,” “USA,” “@neurIST,” “Japan 1,” and “Japan 2,” respectively. “+” indicates same direction as previously
published aneurysm risk SNP; “” indicates opposite direction; “.” indicates absence of the SNP in target cohort.
†
These 2 SNPs are independent (r2=0.06).
‡
These 2 SNPs are independent (r2=0.24).
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Jagiellonian University Medical College K/ZDS/001456. The
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nities, which is performed as a collaborative study supported by
National Heart, Lung, and Blood Institute contracts (HHSN268
201100005C, HHSN268201100006C, HHSN26820110000
7C, HHSN268201100008C, HHSN268201100009C, HHSN2
68201100010C, HHSN268201100011C, and HHSN26820
110012C), R01HL087641, R01HL59367, and R01HL086694;
National Human Genome Research Institute contract
U01HG004402; and NIH contract HHSN268200625226C.
Neurocognitive data were collected by U01 HL096812,
HL096814, HL096899, HL096902, and HL096917 with previ-
ous brain MRI examinations funded by R01-HL70825.
The @neurIST project is supported by the 6th framework
program of the European Commission (www.aneurist.org)
FP6-IST-2004–027703.
AAA GWAS data provided by the Aneurysm Consortium
were funded by the Wellcome Trust (Award No. 084695) and
makes use of data generated by the WTCCC. A full list of the
investigators who contributed to the generation of the data is
available from www.wtccc.org.uk. Funding for the WTCCC
project was provided by the Wellcome Trust under awards
076113 and 085475. Funding for the New Zealand project
was provided by the Health Research Council of New Zealand
(08-75, 14-155). The Geisinger project was funded, in part, by
the Pennsylvania Commonwealth Universal Research
Enhancement Program, the Geisinger Clinical Research Fund,
the American Heart Association, and the Ben Franklin
Technology Development Fund of Pennsylvania. The eMERGE
Network is funded by the NHGRI, with additional funding from
the NIGMS through the following grants: U01HG004438 to
Johns Hopkins University; U01HG004424 to The Broad
Institute; U01HG004438 to CIDR; U01HG004610 and
U01HG006375 to Group Health Cooperative; U01HG
004608 to Marshfield Clinic; U01HG006389 to Essentia
Institute of Rural Health; U01HG04599 and U01HG006379
to Mayo Clinic; U01HG004609 and U01HG006388 to
Northwestern University; U01HG04603 and U01HG006378
to Vanderbilt University; U01HG006385 to the Coordinating
Center; U01HG006382 to Geisinger Health System; and
U01HG006380 to Icahn School of Medicine Mount Sinai.
Vanderbilt’s data set(s) used for the analyses described were
obtained from Vanderbilt University Medical Center’s BioVU,
which is supported by institutional funding and by the National
Center for Research Resources (Grant UL1 RR024975-01;
which is now at the National Center for Advancing Transla-
tional Sciences: Grant 2 UL1 TR000445-06).
The project that created the data regarding the TAA
cohort was supported by grants from the NIH (P50-
HL083794 and R01-HL62594; UL1RR024148 and
UL1RR025758 [CTSA]; K08-HL080085), as well as the Doris
Duke Charitable Trust, the Vivian L. Smith Foundation, the
TexGen Foundation, and the Thoracic Surgery Foundation for
Research and Education.
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